(Hypertension. 2000;36:97.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the First Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan.
| Abstract |
|---|
|
|
|---|
50% of the activity in control vessels.
Moreover, cGMP-dependent protein kinase (PKG) protein levels and PKG
enzyme activity were decreased in Tg vessels. These observations
indicate that chronic overexpression of eNOS in the
endothelium resulted in resistance to the
NO/cGMP-mediated vasodilators and that at least 2 distinct mechanisms
might be involved: one is reduced sGC activity, and the other is a
decrease in PKG protein levels. We reported for the first time that
increased NO release from the endothelium reduces sGC
and PKG activity in mice. These data may provide a new insight into the
mechanisms of nitrate tolerance and cross tolerance to
nitrovasodilators.
Key Words: nitric oxide synthase mice, transgenic guanylyl cyclase protein kinases
| Introduction |
|---|
|
|
|---|
Recently, we generated transgenic (Tg) mice overexpressing the bovine eNOS gene in endothelial cells. The Tg mice exhibited increased basal NO production and basal cGMP levels in the vascular wall. Furthermore, in previous reports, we found that the overproduction of NO caused reduced endothelium-dependent and NO-mediated relaxations without changes in cAMP-mediated relaxation.5 6 Those were the first reports indicating that increased intrinsic NO induced resistance to NO-mediated vasodilators. This alteration in vascular reactivity resembles "nitrate tolerance." Organic nitrates induce vasodilatation by releasing NO and are in widespread use as therapeutic agents for the treatment of myocardial ischemia and heart failure. However, chronic treatment of organic nitrates or NO donors leads to the development of nitrate tolerance, which sometimes yields a therapeutic limitation. The mechanism of nitrate tolerance in humans has been the subject of intense debate but remains poorly defined. The present study was undertaken to clarify the mechanisms of reduced relaxation to NO/cGMP-mediated vasodilators in eNOS-Tg mice. The results might help to elucidate one of the mechanisms of nitrate tolerance.
| Methods |
|---|
|
|
|---|
(PGF2
), acetylcholine (ACh), sodium
nitroprusside (SNP), 8-bromoguanosine-cGMP (8Br-cGMP),
NG-nitro-L-arginine
methyl ester (L-NAME), and other drugs were purchased from Sigma
Chemical Co. Atrial natriuretic peptide (ANP) was purchased
from the Peptide Institute.
Animals
We have generated Tg mice overexpressing the bovine eNOS gene in
the endothelium by using the murine preproendothelin-1
promoter.5 Heterozygous Tg mice and their littermate
control mice, at 12 to 16 weeks of age, were used in the
present study. To inhibit NO synthase chronically, mice were
provided water containing 1 mg/mL L-NAME for 3 weeks. All animal
experiments were conducted according to the Guidelines for Animal
Experimentation at Kobe University School of Medicine.
Measurement of NO Release
Plasma nitrite and nitrate (NOx) levels were measured as nitrite
by using the Griess reaction after enzymatic conversion by nitrate
reductase as previously described.5 NO release from the ex
vivo aorta was measured by examining the production of nitrite
with the use of a NOx analyzer (ozone chemiluminescence) as
previously described.7 The mouse aorta was incubated in
O2-saturated Krebs solution containing 30
µmol/L ACh at 37°C for 60 minutes. After these preparations, the
buffer was removed and used for the assay.
Studies of Vascular Reactivity Ex Vivo
Isometric tension was recorded as previously
described.5 In the experiments with L-NAME pretreatment,
the drug was given in an organ bath 30 minutes before precontraction.
The EC value for each experiment was obtained from a sigmoid logistic
curve.
Detection of Superoxide Anion
Aortic rings were incubated with a Cu-Zn superoxide dismutase
inhibitor (diethyldithiocarbamate) for 30 minutes at
37°C, and vascular superoxide levels were measured by use of
lucigenin chemiluminescence according to the method modified from that
of Münzel et al.8
Measurement of cGMP Levels in Aorta
Aortas from control and Tg mice were incubated in
O2-saturated Krebs solution at 37°C for 60
minutes. After the preparation, the buffer was replaced with Krebs
solution containing either SNP or ANP, and 1 minute later, the aorta
was rapidly frozen in liquid nitrogen. Samples were prepared, and cGMP
was measured as previously described.5
Measurements of sGC Protein Levels and Activity in Aorta
A crude soluble extract of the aorta from control and from Tg
mice was obtained and analyzed by Western blot analysis
with the use of 8% SDS polyacrylamide gels. After
electrophoresis, protein was transferred to a nitrocellulose membrane.
Blots were then incubated in a blocking buffer consisting of 5% nonfat
dry milk for 2 hours at room temperature and incubated overnight at
4°C with rabbit polyclonal sGC IgG (dilution 1:1000, Calbiochem).
Immunoreactive bands were visualized by use of an ECL detection kit
(Amersham) and quantified by densitometry. The sGC assay was performed
according to the method described previously.9
Immunological Quantification and Assay of PKG in Aorta
Western blot analysis for PKG was performed with the use
of 12% SDS polyacrylamide gels. After electrophoresis, protein
was transferred to a nitrocellulose membrane. After incubation with
blocking buffer, blots were incubated overnight at 4°C with rabbit
polyclonal PKG IgG (dilution 1:300, Calbiochem), which recognizes
PKG-I
and -Iß. Immunoreactive bands were visualized and quantified
by densitometry as described above. PKG enzyme activity was measured
according to the method of Diwan et al10 with some
modifications.
Statistics
Data are presented as mean±SEM. An unpaired Student
t test was used to detect significant differences when 2
groups were compared. Statistical analysis for multiple
comparisons was performed by ANOVA with the Bonferroni correction. A
value of P<0.05 was considered to be statistically
significant.
| Results |
|---|
|
|
|---|
|
Comparison of Contractions to KCl and PGF2
Contractions to 40 mmol/L KCl were significantly reduced in
vessels from Tg mice compared with control mice (1.52±0.04 versus
1.28±0.05 g, respectively; P<0.05). Similarly, the
receptor-mediated contractions to PGF2
were
also attenuated in vessels from Tg mice compared with vessels from
control mice (data not shown).
Reduced Relaxations to NO/cGMP-Mediated Vasodilators in
eNOS-Tg Mice
In accordance with our previous report,5 we found
that ACh- and SNP-induced relaxations were significantly reduced in
vessels from Tg mice compared with vessels from control mice (Figure 2a and 2b). We also confirmed that
ATP-
-Sinduced relaxation was reduced in Tg mice (data not shown).
Indomethacin had no effects on those vasorelaxations
(data not shown). To clarify the mechanisms of the reduced NO-mediated
relaxations, we examined responses to other cGMP-dependent vasodilators
(ANP and 8Br-cGMP). Relaxations to ANP were significantly reduced in
vessels from Tg mice compared with vessels from control mice, as
measured by shifts in EC (0.29±0.07 versus 0.67±0.10 µmol/L,
respectively) and by maximal relaxations (97.9±31.7% versus
91.8±2.0%, respectively; P<0.01; Figure 2c).
Likewise, relaxations to a cGMP analogue, 8Br-cGMP, were also
significantly reduced in vessels from Tg mice compared with control
mice, as measured by shifts in EC (Table 1) and by maximal relaxations
(74.3±3.7% versus 96.8±1.2%, respectively; P<0.01;
Figure 2d). On the other hand, as we reported already,
cAMP-mediated vasorelaxations were not different between control and Tg
mice.5
|
|
Effects of L-NAME Pretreatment on Vascular Reactivities
For the L-NAME study, control and Tg mice were provided with water
containing 1 mg/mL L-NAME for 3 weeks to inhibit NOS chronically, and
then ex vivo experiments were performed with 100 µmol/L L-NAME
in the organ baths. L-NAME treatment enhanced the sensitivities to both
SNP and 8Br-cGMP in both genotypes. Chronic L-NAME treatment
reversed the reduced responses in vessels from Tg mice to levels
similar to those in vessels from L-NAMEtreated control mice (Figure 3, Table 1).
|
Vascular Superoxide Levels
Increased superoxide production from the
endothelium was shown in a rabbit model of nitrate
tolerance.8 To examine the contribution of increased
superoxide production to the vascular hyporeactivity in our
mouse model, steady-state vascular superoxide levels were measured by
use of lucigenin chemiluminescence. Superoxide production from
the aorta with endothelium was not significantly
different between the 2 genotypes (for control mice, 46.4±6.4
arbitrary units, n=12; for Tg mice, 42.1±5.8 arbitrary units, n=10).
Moreover, Mn-tetrakis-4-benzoic acid porphyrin chloride (Calbiochem), a
cell-permeable superoxide dismutase mimetic and peroxynitrite
scavenger, could not reverse the reduced relaxation in Tg mice (data
not shown).
NO DonorInduced cGMP Production Is Reduced in
eNOS-Tg Mice
As we reported previously, basal cGMP levels increased in the
aortas from Tg mice compared with those from control
mice.5 6 On the contrary, cGMP levels stimulated by SNP
were significantly reduced in the aortas from Tg mice compared with
those from control mice (Table 2).
However, cGMP levels stimulated by ANP were not different in the 2
groups (Table 2). These results suggest that cGMP
production by sGC was reduced but that cGMP production
by particulate guanylate cyclase was not changed in Tg
mice.
|
Reduced sGC Enzyme Activity in eNOS-Tg Aorta
We examined sGC protein levels with the use of anti-sGC antibody,
which mainly recognizes ß1 subunits. There were
no significant differences in aortic sGC protein levels between the 2
groups (Figure 4a). However, in vitro sGC
activity was markedly reduced in the Tg aorta compared with the control
aorta (Figure 4b).
|
Reduced PKG Levels and Enzyme Activity in eNOS-Tg Aorta
Protein levels of aortic PKG detected by Western blotting were
decreased
20% in Tg mice compared with control mice (Figure 5a and 5b). Moreover, PKG enzyme activity
in the aorta detected by an assay that used protein kinasespecific
substrates was also reduced in Tg mice compared with control mice
(70.5±7.4 versus 106.6±9.1 pmol ·
mg-1 · min-1,
respectively; P<0.05; Figure 5c).
|
| Discussion |
|---|
|
|
|---|
Münzel et al8 reported that increased superoxide
production from endothelial cells induced
inactivation of NO and caused nitrate tolerance in the rabbit model. An
augmentation of vasoconstriction due to increased endothelin-1
production was shown in that model.15 On the other
hand, vascular superoxide levels in eNOS-Tg mice were not increased
compared with those levels in control mice. Moreover, in contrast to
the rabbit nitrate tolerance model, contractions to KCl and
PGF2
were reduced in vessels from Tg mice.
Therefore, an increase in superoxide production does not relate
to the resistance to NO in eNOS-Tg mice. Regarding the impaired
biotransformation of nitrovasodilators to NO12 and an
increased phosphodiesterase activity,14 both are unlikely
related to the reduced relaxation in our Tg mice, because
endothelium-dependent relaxation was reduced and
cGMP-selective phosphodiesterase inhibitors
(zaprinast)14 could not reverse the reduced response (data
not shown).
In the present study, we demonstrated that at least 2 distinct mechanisms were associated with the resistance to NO. One is reduced cGMP elevations in response to the vasodilators, and the other is decreased PKG protein levels. Several reports have shown that the desensitization of sGC is associated with nitrate tolerance,9 13 and our finding is consistent with them. Moncada et al16 reported that vascular reactivity to nitrovasodilators was increased by inhibiting basal NO release from the endothelium. They showed that SNP-induced increases in cGMP were significantly potentiated by removal of the endothelium or by eNOS inhibition. They further reported that the specific supersensitivity to nitrovasodilators, which follows removal of the basal NO release, occurs at the level of its receptor sGC. Recently, Faraci et al17 reported that relaxation of the carotid artery to NO was enhanced in eNOS knockout mice compared with wild-type mice. In the present study, in vitro sGC activity was attenuated in aortas from Tg mice compared with those from control mice, whereas sGC protein levels were not changed (Figure 4). Moreover, we demonstrated that the inhibition of basal NO release with chronic L-NAME treatment could reverse the reduced relaxations (Figure 3, Table 1). These results are consistent with the concept of altered vascular reactivity at the level of sGC after changes in the basal NO release.16
The reduced vascular reactivity cannot be explained by the reduced sGC activity alone. Indeed, despite the reduced relaxation to ANP, there was no difference in cGMP elevations by ANP administration (Figure 2c, Table 2). Moreover, 8Br-cGMPmediated relaxation was also reduced in Tg mice (Figure 2d). Thus, we further examined the downstream pathway and found the reduced expression and activity of PKG. We demonstrated that protein levels and enzyme activity of PKG were significantly reduced in Tg mice (Figure 5). Until recently, PKG and its downstream pathway were not thought to be associated with nitrate tolerance. However, Matsumoto et al18 reported that treatment of isolated canine coronary arteries with nitroglycerin induced hyporesponsiveness not only to nitrovasodilators but also to ANP and 8Br-cGMP. Furthermore, Soff et al19 demonstrated that continuous exposure to nitrovasodilators suppressed PKG transcription and resulted in reduced PKG protein levels in rat vascular smooth muscle cells in vivo and in vitro. They suggested that the reduced PKG might contribute to the mechanisms of nitrate tolerance. Our finding is in accordance with their data; thus, it is likely that the reduced PKG expression is at least partly responsible for the resistance to NO/cGMP-mediated vasodilators in eNOS-Tg mice. In addition, we cannot deny the possibility that the downstream pathway of PKG may also be altered and involved in the mechanisms of the reduced response to NO in Tg mice.
Other mechanisms extraneous to the vessel wall were thought to be responsible for nitrate tolerance, and the phenomenon induced by these mechanisms was called pseudotolerance. These mechanisms include neurohumoral counterregulation and intravascular volume expansion.20 However, there was no difference in plasma concentrations of catecholamines, renin, and endothelin-1 between control and Tg mice.5
Recently, it has been reported by several investigators that transient
eNOS gene transfer to the vascular wall changes the vascular
reactivity.21 22 23 In contrast with our findings,
adenovirus-mediated eNOS gene transfer to rabbit carotid arteries has
been reported to enhance endothelium-dependent
relaxations.21 22 The period of overexpressing the eNOS
gene might be responsible for the difference in vascular reactivity
between their studies and ours. In their gene transfer studies, the
period of overexpressing the eNOS gene was only 1 to several days
before vascular tonus experiments.21 22 In our Tg mice,
eNOS was overexpressed chronically and throughout the lives of the
mice. Regarding contractile responses, both receptor-independent (KCl)
and receptor-mediated (PGF2
) contractions were
reduced in vessels from eNOS-Tg mice. The same observation applies to
the studies of virus-mediated eNOS gene transfer. Hemagglutinating
virus of Japan liposomemediated eNOS gene transfer in injured rat
carotid arteries resulted in reduced contractions to
KCl.23 Moreover, contractions to phenylephrine
were also reduced in adenovirus-mediated eNOS genetransferred
arteries.22 However, eNOS gene transfer did not change
phenylephrine-induced contraction in other
reports.21 The discrepancy may be due to the difference in
the extent of eNOS overexpression in these studies. The diminished
sensitivity to contractile agonists is commonly seen in the condition
with increased basal NO release from the vascular wall.
In conclusion, the eNOS-overexpressing mice displayed reduced relaxant responses in the NO/cGMP pathway but not in the cAMP pathway. At least 2 distinct mechanisms are involved: one is reduced sGC activity, and the other is reduced PKG protein levels. Furthermore, the reduced reactivity could be reversed by chronic NOS inhibition. These findings indicate that not only exogenous NO but also intrinsic NO from the endothelium could induce reduced vascular responses to nitroglycerin and other nitrovasodilators, like nitrate tolerance. The implications of these findings will not be confined to the Tg mice, and our mouse model will be a novel useful tool to explore the real mechanisms of tolerance to nitrovasodilators. Further studies are warranted to reveal relevant roles of NO in physiological and pathological situations.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received November 30, 1999; first decision January 17, 2000; accepted February 15, 2000.
| References |
|---|
|
|
|---|
2.
Moncada S, Higgs EA. The L-arginine-nitric oxide
pathway. N Engl J Med.. 1993;329:20022012.
3.
Ignarro L. Biological actions and properties of
endothelium-derived nitric oxide formed and released
from artery and vein. Circ Res. 1989;65:121.
4. Lincoln TM, Corwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7:328338.[Abstract]
5. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:20612071.[Medline] [Order article via Infotrieve]
6.
Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Ueyama T,
Ishida T, Inoue N, Hirata K, Akita H, Yokoyama M. Resistance to
endotoxin shock in transgenic mice overexpressing
endothelial nitric oxide synthase.
Circulation.. 2000;101:931937.
7.
Hirata K, Kuroda R, Sakoda T, Katayama M, Inoue N,
Suematsu M, Kawashima S, Yokoyama M. Inhibition of
endothelial nitric oxide synthase activity by protein
kinase C. Hypertension. 1995;25:180185.
8. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross tolerance. J Clin Invest. 1995;95:187194.
9. Axelsson KL, Andersson RGG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol. 1983;88:7179.[Medline] [Order article via Infotrieve]
10. Diwan AH, Thompson WJ, Lee AK, Strada SJ. Cyclic GMP-dependent protein kinase activity in rat pulmonary microvascular endothelial cells. Biochem Biophys Res Commun. 1994;202:728735.[Medline] [Order article via Infotrieve]
11.
Parker JD, Parker JO. Nitrate therapy for stable angina
pectoris. N Engl J Med. 1998;338:520531.
12.
Needleman P, Johnson EM Jr. Mechanism of tolerance
development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709715.
13. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol. 1986;35:35253531.[Medline] [Order article via Infotrieve]
14. Silver PJ, Pagani ED, de Garavilla L, VanAller GS, Volberg ML, Pratt PF, Buchholz RA. Reversal of nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 1991;199:141142.[Medline] [Order article via Infotrieve]
15.
Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison
DG. Evidence for a role of endothelin 1 and protein kinase C in nitrate
tolerance. Proc Natl Acad Sci U S A. 1995;92:52245248.
16.
Moncada S, Rees DD, Schulz R, Palmer RMJ. Development
and mechanism of a specific supersensitivity to nitrovasodilators after
inhibition of vascular nitric oxide synthesis in vivo. Proc Natl
Acad Sci U S A. 1991;88:21662170.
17.
Faraci FM, Sigmund CD, Shesely EG, Maeda N, Heistad DD.
Responses of carotid artery in mice deficient in expression of the gene
for endothelial NO synthase. Am J
Physiol. 1998;274:H564H570.
18. Matsumoto T, Okamura T, Kinoshita M, Toda N. Interactions of nitrovasodilators and atrial natriuretic peptide in isolated dog coronary arteries. Eur J Pharmacol. 1993;237:3137.[Medline] [Order article via Infotrieve]
19. Soff GA, Cornwell TL, Cundiff DL, Gately S, Lincoln TM. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest. 1997;100:25802587.[Medline] [Order article via Infotrieve]
20.
Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO.
Counter-regulatory response to continuous and intermittent therapy with
nitroglycerin. Circulation. 1991;84:23362345.
21.
Ooboshi H, Chu Y, Rios CD, Faraci FM, Davidson BL,
Heistad DD. Altered vascular function after adenovirus-mediated
overexpression of endothelial nitric oxide synthase.
Am J Physiol. 1997;273:H265H270.
22.
Kullo IJ, Mozes G, Schwartz RS, Gloviczki P, Crotty TB,
Barber DA, Katusic ZS, OBrien T. Adventitial gene transfer of
recombinant endothelial nitric oxide synthase to rabbit
carotid arteries alters vascular reactivity. Circulation. 1997;96:22542261.
23.
von der Leyen HE, Gibbons GH, Morishita R, Lewis NP,
Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy
inhibiting neointimal vascular lesion: in vivo transfer of
endothelial cell nitric oxide synthase gene. Proc
Natl Acad Sci U S A. 1995;92:11371141.
This article has been cited by other articles:
![]() |
E. J. Halvey, J. Vernon, B. Roy, and J. Garthwaite Mechanisms of Activity-dependent Plasticity in Cellular Nitric Oxide-cGMP Signaling J. Biol. Chem., September 18, 2009; 284(38): 25630 - 25641. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Perkins, D. O. Warner, and K. A. Jones Prolonged treatment of porcine pulmonary artery with nitric oxide decreases cGMP sensitivity and cGMP-dependent protein kinase specific activity Am J Physiol Lung Cell Mol Physiol, January 1, 2009; 296(1): L121 - L129. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. van Deel, D. Merkus, R. van Haperen, M. C. de Waard, R. de Crom, and D. J. Duncker Vasomotor control in mice overexpressing human endothelial nitric oxide synthase Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1144 - H1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Perkins, M. Taniguchi, D. O. Warner, E. N. Chini, and K. A. Jones Reduction in soluble guanylyl cyclase-specific activity following prolonged treatment of porcine pulmonary artery with nitric oxide Am J Physiol Lung Cell Mol Physiol, July 1, 2007; 293(1): L84 - L95. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Petersen, F. Wiesmann, L. E. Hudsmith, M. D. Robson, J. M. Francis, J. B. Selvanayagam, S. Neubauer, and K. M. Channon Functional and Structural Vascular Remodeling in Elite Rowers Assessed by Cardiovascular Magnetic Resonance J. Am. Coll. Cardiol., August 15, 2006; 48(4): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Tan, C.-Y. Chai, J.-R. Wu, J.-L. Yeh, I.-J. Chen, A.-L. Kwan, A. Y. Jeng, H.-Y. Yang, M.-H. Lee, and Z.-K. Dai Differential Change in Expression of Pulmonary ET-1 and eNOS in Rats After Chronic Left Ventricular Pressure Overload. Experimental Biology and Medicine, June 1, 2006; 231(6): 948 - 953. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Chou, C.-Y. Chai, J.-R. Wu, M.-S. Tan, C.-C. Chiu, I.-J. Chen, A. Y. Jeng, C.-I Chang, A.-L. Kwan, and Z.-K. Dai The Effects of Debanding on the Lung Expression of ET-1, eNOS, and cGMP in Rats with Left Ventricular Pressure Overload. Experimental Biology and Medicine, June 1, 2006; 231(6): 954 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Resnik, J. Herron, M. Keck, D. Sukovich, B. Linden, and D. N. Cornfield Chronic intrauterine pulmonary hypertension selectively modifies pulmonary artery smooth muscle cell gene expression Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L426 - L433. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Diez-Marques, M. P. Ruiz-Torres, M. Griera, S. Lopez-Ongil, M. Saura, D. Rodriguez-Puyol, and M. Rodriguez-Puyol Arg-Gly-Asp (RGD)-containing peptides increase soluble guanylate cyclase in contractile cells Cardiovasc Res, February 1, 2006; 69(2): 359 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Browner, N. B. Dey, K. D. Bloch, and T. M. Lincoln Regulation of cGMP-dependent Protein Kinase Expression by Soluble Guanylyl Cyclase in Vascular Smooth Muscle Cells J. Biol. Chem., November 5, 2004; 279(45): 46631 - 46636. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Kang, F. J. Tamarkin, M. A. Wheeler, and R. M. Weiss Rapid Up-Regulation of Endothelial Nitric-Oxide Synthase in a Mouse Model of Escherichia coli Lipopolysaccharide-Induced Bladder Inflammation J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 452 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-L. Xu, V. Gavrilyuk, H. M. Wolde, V. L. Baughman, and D. A. Pelligrino Regulation of rat pial arteriolar smooth muscle relaxation in vivo through multidrug resistance protein 5-mediated cGMP efflux Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H2020 - H2027. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gao, S. Dhanakoti, E. M. Trevino, X. Wang, F. C. Sander, A. D. Portugal, and J. U. Raj Role of cGMP-dependent protein kinase in development of tolerance to nitric oxide in pulmonary veins of newborn lambs Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L786 - L792. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Jones, J. J. M. Greer, A. K. Kakkar, P. D. Ware, R. H. Turnage, M. Hicks, R. van Haperen, R. de Crom, S. Kawashima, M. Yokoyama, et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H276 - H282. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Pilz and D. E. Casteel Regulation of Gene Expression by Cyclic GMP Circ. Res., November 28, 2003; 93(11): 1034 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gerzanich, A. Ivanov, S. Ivanova, J. B. Yang, H. Zhou, Y. Dong, and J. M. Simard Alternative Splicing of cGMP-Dependent Protein Kinase I in Angiotensin-Hypertension: Novel Mechanism for Nitrate Tolerance in Vascular Smooth Muscle Circ. Res., October 31, 2003; 93(9): 805 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Friebe and D. Koesling Regulation of Nitric Oxide-Sensitive Guanylyl Cyclase Circ. Res., July 25, 2003; 93(2): 96 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zanetti, L. V. d'Uscio, I. Kovesdi, Z. S. Katusic, and T. O'Brien In Vivo Gene Transfer of Inducible Nitric Oxide Synthase to Carotid Arteries From Hypercholesterolemic Rabbits Stroke, May 1, 2003; 34(5): 1293 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. d'Uscio, S. Milstien, D. Richardson, L. Smith, and Z. S. Katusic Long-Term Vitamin C Treatment Increases Vascular Tetrahydrobiopterin Levels and Nitric Oxide Synthase Activity Circ. Res., January 10, 2003; 92(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Amano, H. Matsubara, O. Iba, M. Okigaki, S. Fujiyama, T. Imada, H. Kojima, Y. Nozawa, S. Kawashima, M. Yokoyama, et al. Enhancement of Ischemia-Induced Angiogenesis by eNOS Overexpression Hypertension, January 1, 2003; 41(1): 156 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Frame, R. J. Fox, D. Kim, A. Mohan, B. C. Berk, and C. Yan Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2377 - H2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Scotland, M. Morales-Ruiz, Y. Chen, J. Yu, R. D. Rudic, D. Fulton, J.-P. Gratton, and W. C. Sessa Functional Reconstitution of Endothelial Nitric Oxide Synthase Reveals the Importance of Serine 1179 in Endothelium-Dependent Vasomotion Circ. Res., May 3, 2002; 90(8): 904 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nishimatsu, Y. Hirata, T. Shindo, H. Kurihara, M. Kakoki, D. Nagata, H. Hayakawa, H. Satonaka, M. Sata, A. Tojo, et al. Role of Endogenous Adrenomedullin in the Regulation of Vascular Tone and Ischemic Renal Injury: Studies on Transgenic/Knockout Mice of Adrenomedullin Gene Circ. Res., April 5, 2002; 90(6): 657 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sellak, X. Yang, X. Cao, T. Cornwell, G. A. Soff, and T. Lincoln Sp1 Transcription Factor as a Molecular Target for Nitric Oxide- and Cyclic Nucleotide-Mediated Suppression of cGMP-Dependent Protein Kinase-I{alpha} Expression in Vascular Smooth Muscle Cells Circ. Res., March 8, 2002; 90(4): 405 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gros, R. Van Wert, X. You, E. Thorin, and M. Husain Effects of age, gender, and blood pressure on myogenic responses of mesenteric arteries from C57BL/6 mice Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H380 - H388. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Black, L. S. Sanchez, E. Mata-Greenwood, J. M. Bekker, R. H. Steinhorn, and J. R. Fineman sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1051 - L1057. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gilbert, J. Tremblay, and E. Thorin Endothelium-Derived Endothelin-1 Reduces Cerebral Artery Sensitivity to Nitric Oxide by a Protein Kinase C-Independent Pathway Stroke, October 1, 2001; 32(10): 2351 - 2355. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kawashima, T. Yamashita, M. Ozaki, Y. Ohashi, H. Azumi, N. Inoue, K.-i. Hirata, Y. Hayashi, H. Itoh, and M. Yokoyama Endothelial NO Synthase Overexpression Inhibits Lesion Formation in Mouse Model of Vascular Remodeling Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 201 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Frame, R. J. Fox, D. Kim, A. Mohan, B. C. Berk, and C. Yan Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2377 - H2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sellak, X. Yang, X. Cao, T. Cornwell, G. A. Soff, and T. Lincoln Sp1 Transcription Factor as a Molecular Target for Nitric Oxide- and Cyclic Nucleotide-Mediated Suppression of cGMP-Dependent Protein Kinase-I{alpha} Expression in Vascular Smooth Muscle Cells Circ. Res., March 8, 2002; 90(4): 405 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nishimatsu, Y. Hirata, T. Shindo, H. Kurihara, M. Kakoki, D. Nagata, H. Hayakawa, H. Satonaka, M. Sata, A. Tojo, et al. Role of Endogenous Adrenomedullin in the Regulation of Vascular Tone and Ischemic Renal Injury: Studies on Transgenic/Knockout Mice of Adrenomedullin Gene Circ. Res., April 5, 2002; 90(6): 657 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Scotland, M. Morales-Ruiz, Y. Chen, J. Yu, R. D. Rudic, D. Fulton, J.-P. Gratton, and W. C. Sessa Functional Reconstitution of Endothelial Nitric Oxide Synthase Reveals the Importance of Serine 1179 in Endothelium-Dependent Vasomotion Circ. Res., May 3, 2002; 90(8): 904 - 910. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |